DOCSLIB.ORG

Membranes of Human Neutrophils Secretory Vesicle Membranes And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Membranes of Human Neutrophils Secretory Vesicle Membranes And Comparison of Proteins Expressed on Secretory Vesicle Membranes and Plasma Membranes of Human Neutrophils This information is current as Silvia M. Uriarte, David W. Powell, Gregory C. Luerman, of September 25, 2021. Michael L. Merchant, Timothy D. Cummins, Neelakshi R. Jog, Richard A. Ward and Kenneth R. McLeish J Immunol 2008; 180:5575-5581; ; doi: 10.4049/jimmunol.180.8.5575 http://www.jimmunol.org/content/180/8/5575 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2008/04/01/180.8.5575.DC1 Material http://www.jimmunol.org/ References This article cites 44 articles, 25 of which you can access for free at: http://www.jimmunol.org/content/180/8/5575.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 25, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Comparison of Proteins Expressed on Secretory Vesicle Membranes and Plasma Membranes of Human Neutrophils1 Silvia M. Uriarte,* David W. Powell,*† Gregory C. Luerman,† Michael L. Merchant,* Timothy D. Cummins,* Neelakshi R. Jog,‡ Richard A. Ward,* and Kenneth R. McLeish2*†§ Secretory vesicles are neutrophil intracellular storage granules formed by endocytosis. Understanding the functional consequences of secretory vesicle exocytosis requires knowledge of their membrane proteins. The current study was designed to use proteomic technologies to develop a more complete catalog of secretory vesicle membrane proteins and to compare the proteomes of secretory vesicle and plasma membranes. A total of 1118 proteins were identified, 573 (51%) were present only in plasma membrane- enriched fractions, 418 (37%) only in secretory vesicle-enriched membrane fractions, and 127 (11%) in both fractions. Gene Ontology categorized 373 of these proteins as integral membrane proteins. Proteins typically associated with other intracellular organelles, including nuclei, mitochondria, and ribosomes, were identified in both membrane fractions. Ingenuity Pathway Knowl- Downloaded from edge Base analysis determined that the majority of canonical and functional pathways were significantly associated with proteins from both plasma membrane-enriched and secretory vesicle-enriched fractions. There were, however, some canonical signaling pathways that involved proteins only from plasma membranes or secretory vesicles. In conclusion, a number of proteins were identified that may elucidate mechanisms and functional consequences of secretory vesicle exocytosis. The small number of common proteins suggests that the hypothesis that secretory vesicles are formed from plasma membranes by endocytosis requires more critical evaluation. The Journal of Immunology, 2008, 180: 5575–5581. http://www.jimmunol.org/ irculating neutrophils are capable of undergoing a series Golgi network during neutrophil maturation (1). The intragranule of phenotypic changes that result in their transition from constituents of secretory vesicles include plasma proteins, result- C cells that are poorly responsive to proinflammatory stim- ing in the hypothesis that secretory vesicles are formed by endo- uli to become the primary effector cells of innate immunity. These cytosis and that functional changes from their exocytosis are due phenotypic changes involve the incorporation of proteins from the entirely to incorporation of new molecules into the plasma mem- membranes of intracellular storage granules into the plasma mem- brane (1, 5). Thus, to understand the changes in neutrophil func- brane and the release of proteins stored in granule matrix through tional capability induced by secretory vesicle exocytosis, a com- by guest on September 25, 2021 regulated exocytosis. Granule exocytosis contributes to enhanced prehensive catalog of membrane proteins is required. neutrophil tethering and adhesion to vascular endothelial cells at a Proteomic techniques, which include methods for protein ex- site of inflammation; enhanced migration across blood vessel traction and separation, protein identification and characterization, walls; chemotaxis to a site of microbial invasion; phagocytosis of and database analysis, provide an unbiased approach to identifying invading organisms; and microbicidal activity through a combina- proteins expressed in subcellular compartments (6–9). We re- tion of enzymatic degradation, reactive oxygen species generation, cently published a comprehensive proteomic analysis of neutrophil and release of microbicidal peptides into phagosomes. Neutrophils gelatinase, specific, and azurophil granules (10). Using protein contain a heterologous group of storage granules that have been separation by two-dimensional gel electrophoresis and two-dimen- classified into four subsets based on density and composition: sional HPLC coupled with MALDI-TOF-MS3 and ESI-MS/MS, azurophil (primary) granules, specific (secondary) granules, gela- 286 proteins were identified on one or more granule subsets, many tinase (tertiary) granules, and secretory vesicles (1). These granule of which had not been found previously on neutrophil granules. subsets undergo hierarchical stimulated exocytosis, with secretory The current study was designed to use similar proteomic technol- vesicles the most easily and completely mobilized (2–4). Gelati- ogies to provide a more complete identification of secretory vesicle nase, specific, and azurophil granules are formed from the trans- membrane proteins and to compare those proteins with the proteins expressed on neutrophil plasma membranes. The ability to extract and solubilize membrane proteins is a major limitation to all pro- *Department of Medicine, †Department of Biochemistry and Molecular Biology, and teomic approaches. To overcome this limitation, proteins were ‡Department of Microbiology and Immunology, University of Louisville, Louisville, extracted from membranes using a recently described methanol § KY 40202; and Veterans Affairs Medical Center, Louisville, KY 40206 extraction procedure, followed by two-dimensional HPLC and Received for publication October 29, 2007. Accepted for publication February ESI-MS/MS (11). With this approach, we identified a number of 7, 2008. membrane spanning and membrane associated proteins and uncov- The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance ered significant differences between secretory vesicle-enriched and with 18 U.S.C. Section 1734 solely to indicate this fact. plasma membrane-enriched proteomes. 1 This work was supported by a Merit Review Grant from the Department of Veterans Affairs (to K.R.M.), National Institutes of Health Grants DK62389 (to R.A.W. and K.R.M.) and DK176743 (to D.W.P.), and the Office of Science Financial Assistance Program, Department of Energy (to D.W.P.). 3 Abbreviations used in this paper: MS, mass spectrometry; SCX, strong cation ex- 2 Address correspondence and reprint requests to Dr. Kenneth R. McLeish, Baxter I change; RP, reversed-phase; PAF, protein abundance factor; NCBI, National Center Research Building, University of Louisville, 570 South Preston Street, Louisville, KY for Biotechnology Information; IPKB, Ingenuity Pathways Knowledge Base; 40202. E-mail address: [email protected] SNARE, soluble NSF attachment receptor. www.jimmunol.org 5576 NEUTROPHIL SECRETORY VESICLE PROTEOME Materials and Methods acid and mobile phase B: 80% acetonitrile/0.1% formic acid). Spectra were Neutrophil isolation acquired with a LTQ linear ion trap mass spectrometer (Thermo Fisher Sci- entific). During LC-MS/MS analysis, the mass spectrometer performed data- Neutrophils were isolated from healthy donors using plasma-Percoll gradients dependent acquisition with a full MS scan between 300 and 2000 mass to as described by Haslett et al. (12). Trypan blue staining revealed that at least change ratio followed by five MS/MS scans (35% collision energy) on the five 97% of cells were neutrophils with Ͼ95% viability. After isolation, neutro- most intense ions from the preceding MS scan. Data acquisition was per- phils were suspended in Krebs-Ringer phosphate buffer (pH 7.2) at 4 ϫ 107 formed using dynamic exclusion with a repeat count of 30 anda1and3min cells/ml and treated with 5 mM diisopropyl fluorophosphate for 10 min on ice exclusion duration window. to inhibit proteases (13). Extensive evaluation using respiratory burst activity and granule exocytosis indicates that this isolation technique does not prime Mass spectral data interpretations neutrophils. The Human Studies Committee of the University of Louisville approved the use of human donors. The acquired mass spectrometric data were searched against a human protein database (human RefSeq) using the Sequest algorithm and a commercial com- Plasma membrane and secretory vesicle
Load more

Recommended publications
  • Exosomes from Nischarin-Expressing Cells Reduce Breast Cancer Cell Motility and Tumor Growth
    Author Manuscript Published OnlineFirst on January 11, 2019; DOI: 10.1158/0008-5472.CAN-18-0842 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Exosomes from Nischarin-Expressing Cells Reduce Breast Cancer Cell Motility and tumor growth Mazvita Maziveyi1,7, Shengli Dong1, Somesh Baranwal2, Ali Mehrnezhad3, Rajamani Rathinam4, Thomas M. Huckaba5, Donald E. Mercante6, Kidong Park3, Suresh K. Alahari1 1Department of Biochemistry and Molecular Biology, LSUHSC School of Medicine, New Orleans, LA, USA 2Center of Biochemistry and Microbial Science, Central University of Punjab, Bathinda-151001, India 3Department of Electrical Engineering and Computer Engineering, Louisiana State University, Baton Rouge, LA, USA 4Wayne State University, Detroit, MI, USA 5Department of Biology, Xavier University of Louisiana, New Orleans, LA, USA 6School of Public Health, LSUHSC School of Medicine, New Orleans, LA, USA 7Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, Texas *Corresponding author; Suresh K. Alahari, PhD; Fred G. Brazda Professor of Biochemistry, LSUHSC School of Medicine, New Orleans, LA 70112, USA; Tel: 504-568-4734 [email protected] Running Title: Nischarin regulates exosome production Conflicts of Interest No potential conflicts of interest were disclosed. Downloaded from cancerres.aacrjournals.org on September 29, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on January 11, 2019; DOI: 10.1158/0008-5472.CAN-18-0842 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Abstract: Exosomes are small extracellular microvesicles that are secreted by cells when intracellular multivesicular bodies (MVB) fuse with the plasma membrane.
    [Show full text]
  • Download Download
    Supplementary Figure S1. Results of flow cytometry analysis, performed to estimate CD34 positivity, after immunomagnetic separation in two different experiments. As monoclonal antibody for labeling the sample, the fluorescein isothiocyanate (FITC)- conjugated mouse anti-human CD34 MoAb (Mylteni) was used. Briefly, cell samples were incubated in the presence of the indicated MoAbs, at the proper dilution, in PBS containing 5% FCS and 1% Fc receptor (FcR) blocking reagent (Miltenyi) for 30 min at 4 C. Cells were then washed twice, resuspended with PBS and analyzed by a Coulter Epics XL (Coulter Electronics Inc., Hialeah, FL, USA) flow cytometer. only use Non-commercial 1 Supplementary Table S1. Complete list of the datasets used in this study and their sources. GEO Total samples Geo selected GEO accession of used Platform Reference series in series samples samples GSM142565 GSM142566 GSM142567 GSM142568 GSE6146 HG-U133A 14 8 - GSM142569 GSM142571 GSM142572 GSM142574 GSM51391 GSM51392 GSE2666 HG-U133A 36 4 1 GSM51393 GSM51394 only GSM321583 GSE12803 HG-U133A 20 3 GSM321584 2 GSM321585 use Promyelocytes_1 Promyelocytes_2 Promyelocytes_3 Promyelocytes_4 HG-U133A 8 8 3 GSE64282 Promyelocytes_5 Promyelocytes_6 Promyelocytes_7 Promyelocytes_8 Non-commercial 2 Supplementary Table S2. Chromosomal regions up-regulated in CD34+ samples as identified by the LAP procedure with the two-class statistics coded in the PREDA R package and an FDR threshold of 0.5. Functional enrichment analysis has been performed using DAVID (http://david.abcc.ncifcrf.gov/)
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,592,444 B2 Khvorova Et Al
    USOO7592444B2 (12) United States Patent (10) Patent No.: US 7,592,444 B2 KhVOrOVa et al. (45) Date of Patent: Sep. 22, 2009 (54) SIRNA TARGETING MYELOID CELL 2003/0228597 A1 12/2003 COWSert LEUKEMIA SEQUENCE 1 2004/OO29275 A1 2/2004 Brown et al. 2004.00541.55 A1 3, 2004 Woolf (75) Inventors: Anastasia Khvorova, Boulder, CO 2004-0063654. A 42004 Davis et al. (US); Angela Reynolds, Conifer, CO S.S. A. 3. Singhofer (US);O O Devin Leake, Denver, CO (US); 2004/O180357 A1 9, 2004 eich William Marshall, Boulder, CO (US); 2004/O192629 A1 9, 2004 Xu et al. Stephen Scaringe, Lafayette, CO (US); 2004/0204380 A1 10, 2004 Ackerman Steven Read, Boulder, CO (US) 2004/0219671 A1 1 1/2004 McSwiggen 2004/024.8296 A1 12/2004 Beresford (73) Assignee: Dharmacon, Inc., Lafayette, CO (US) 2004/0248299 A1 12/2004 Jayasena 2004/0259247 A1 12, 2004 TuSchlet al. (*) Notice: Subject to any disclaimer, the term of this 2005/0048529 A1 3/2005 McSwiggen patent is extended or adjusted under 35 2005/0107328 A1 5/2005 Wyatt U.S.C. 154(b) by 0 days. 2005. O130181 A1 6/2005 McSwiggen 2005/0176O25 A1 8/2005 McSwiggen (21) Appl. No.: 12/378,164 2005, 0181382 A1 8, 2005 Zamore 2005, 0186586 A1 8, 2005 Zamore 2005/0227935 A1 10/2005 McSwiggen (22) Filed: Feb. 11, 2009 2005/0239731 A1 10/2005 McSwiggen 2005.0245475 A1 11/2005 Khvorova (65) Prior Publication Data 2006/0286575 A1 12/2006 Farrell US 2009/O1637O2A1 Jun. 25, 2009 2007/0031844 A1 2/2007 Khvorova 2007,0254.850 A1 11/2007 Lieberman Related U.S.
    [Show full text]
  • Breast Cancer Tumor Suppressors: a Special Emphasis on Novel Protein Nischarin Mazvita Maziveyi and Suresh K
    Published OnlineFirst September 21, 2015; DOI: 10.1158/0008-5472.CAN-15-1395 Cancer Review Research Breast Cancer Tumor Suppressors: A Special Emphasis on Novel Protein Nischarin Mazvita Maziveyi and Suresh K. Alahari Abstract Tumor suppressor genes regulate cell growth and prevent vast number of cellular processes, including neuronal protection spontaneous proliferation that could lead to aberrant tissue and hypotension. The NISCH promoter experiences hypermethy- function. Deletions and mutations of these genes typically lead lation in several cancers, whereas some highly aggressive breast to progression through the cell-cycle checkpoints, as well as cancer cells exhibit genomic loss of the NISCH locus. Further- increased cell migration. Studies of these proteins are important more, we discuss data illustrating a novel role of Nischarin as as they may provide potential treatments for breast cancers. In this a tumor suppressor in breast cancer. Analysis of this new para- review, we discuss a comprehensive overview on Nischarin, a digm may shed light on various clinical questions. Finally, the novel protein discovered by our laboratory. Nischarin, or imida- therapeutic potential of Nischarin is discussed. Cancer Res; 75(20); zoline receptor antisera-selected protein, is a protein involved in a 4252–9. Ó2015 AACR. Introduction (6, 7). It also interacts with LIM kinase (LIMK) in order to prevent cytoskeletal reorganization (8). Typically, scaffold proteins such Breast cancer initiation and progression involve several genetic as Nischarin are characterized as caretaker genes because their events that can activate oncogenes and/or abrogate the function of effects on tumor growth are indirect. tumor suppressor genes. Tumor suppressor genes are commonly lost or deleted in cancers, facilitating the initiation and progres- sion of cancer through several biological events, including cell Discovery of Nischarin proliferation, cell death, cell migration, and cell invasion.
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]
  • Identification of Candidate Genes and Pathways Associated with Obesity
    animals Article Identification of Candidate Genes and Pathways Associated with Obesity-Related Traits in Canines via Gene-Set Enrichment and Pathway-Based GWAS Analysis Sunirmal Sheet y, Srikanth Krishnamoorthy y , Jihye Cha, Soyoung Choi and Bong-Hwan Choi * Animal Genome & Bioinformatics, National Institute of Animal Science, RDA, Wanju 55365, Korea; [email protected] (S.S.); [email protected] (S.K.); [email protected] (J.C.); [email protected] (S.C.) * Correspondence: [email protected]; Tel.: +82-10-8143-5164 These authors contributed equally. y Received: 10 October 2020; Accepted: 6 November 2020; Published: 9 November 2020 Simple Summary: Obesity is a serious health issue and is increasing at an alarming rate in several dog breeds, but there is limited information on the genetic mechanism underlying it. Moreover, there have been very few reports on genetic markers associated with canine obesity. These studies were limited to the use of a single breed in the association study. In this study, we have performed a GWAS and supplemented it with gene-set enrichment and pathway-based analyses to identify causative loci and genes associated with canine obesity in 18 different dog breeds. From the GWAS, the significant markers associated with obesity-related traits including body weight (CACNA1B, C22orf39, U6, MYH14, PTPN2, SEH1L) and blood sugar (PRSS55, GRIK2), were identified. Furthermore, the gene-set enrichment and pathway-based analysis (GESA) highlighted five enriched pathways (Wnt signaling pathway, adherens junction, pathways in cancer, axon guidance, and insulin secretion) and seven GO terms (fat cell differentiation, calcium ion binding, cytoplasm, nucleus, phospholipid transport, central nervous system development, and cell surface) which were found to be shared among all the traits.
    [Show full text]
  • File Download
    Nischarin inhibition alters energy metabolism by activating AMP-activated protein kinase Shengli Dong, Louisiana State University Somesh Baranwal, Louisiana State University AnaPatricia Garcia, Emory University Silvia J. Serrano-Gomez, Louisiana State University Steven Eastlack, Louisiana State University Tomoo Iwakuma, Kansas University Medical Center Donald Mercante, Louisiana State University Franck Mauvais-Jarvis, Tulane University School of Medicine Suresh K. Alahari, Louisiana State University Journal Title: Journal of Biological Chemistry Volume: Volume 292, Number 41 Publisher: American Society for Biochemistry and Molecular Biology | 2017-10-13, Pages 16833-16846 Type of Work: Article | Final Publisher PDF Publisher DOI: 10.1074/jbc.M117.784256 Permanent URL: https://pid.emory.edu/ark:/25593/tdw0b Final published version: http://dx.doi.org/10.1074/jbc.M117.784256 Copyright information: © 2017 by The American Society for Biochemistry and Molecular Biology, Inc. Accessed October 1, 2021 8:18 PM EDT ARTICLE cro Nischarin inhibition alters energy metabolism by activating AMP-activated protein kinase Received for publication, March 2, 2017, and in revised form, August 22, 2017 Published, Papers in Press, August 24, 2017, DOI 10.1074/jbc.M117.784256 Shengli Dong‡, Somesh Baranwal‡§, Anapatricia Garcia¶, Silvia J. Serrano-Gomez‡ʈ, Steven Eastlack‡, Tomoo Iwakuma**, Donald Mercante‡‡, Franck Mauvais-Jarvis§§1, and Suresh K. Alahari‡2 From the ‡Department of Biochemistry and Molecular Biology, School of Medicine, and ‡‡Department of Biostatistics,
    [Show full text]
  • Nuclear PTEN Safeguards Pre-Mrna Splicing to Link Golgi Apparatus for Its Tumor Suppressive Role
    ARTICLE DOI: 10.1038/s41467-018-04760-1 OPEN Nuclear PTEN safeguards pre-mRNA splicing to link Golgi apparatus for its tumor suppressive role Shao-Ming Shen1, Yan Ji2, Cheng Zhang1, Shuang-Shu Dong2, Shuo Yang1, Zhong Xiong1, Meng-Kai Ge1, Yun Yu1, Li Xia1, Meng Guo1, Jin-Ke Cheng3, Jun-Ling Liu1,3, Jian-Xiu Yu1,3 & Guo-Qiang Chen1 Dysregulation of pre-mRNA alternative splicing (AS) is closely associated with cancers. However, the relationships between the AS and classic oncogenes/tumor suppressors are 1234567890():,; largely unknown. Here we show that the deletion of tumor suppressor PTEN alters pre-mRNA splicing in a phosphatase-independent manner, and identify 262 PTEN-regulated AS events in 293T cells by RNA sequencing, which are associated with significant worse outcome of cancer patients. Based on these findings, we report that nuclear PTEN interacts with the splicing machinery, spliceosome, to regulate its assembly and pre-mRNA splicing. We also identify a new exon 2b in GOLGA2 transcript and the exon exclusion contributes to PTEN knockdown-induced tumorigenesis by promoting dramatic Golgi extension and secretion, and PTEN depletion significantly sensitizes cancer cells to secretion inhibitors brefeldin A and golgicide A. Our results suggest that Golgi secretion inhibitors alone or in combination with PI3K/Akt kinase inhibitors may be therapeutically useful for PTEN-deficient cancers. 1 Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine (SJTU-SM), Shanghai 200025, China. 2 Institute of Health Sciences, Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences and SJTU-SM, Shanghai 200025, China.
    [Show full text]
  • Identification and Subcellular Localization of Human Rab5b, a New Member of the Ras-Related Superfamily of Gtpases
    Identification and subcellular localization of human rab5b, a new member of the ras-related superfamily of GTPases. D B Wilson, M P Wilson J Clin Invest. 1992;89(3):996-1005. https://doi.org/10.1172/JCI115683. Research Article Members of the mammalian rab family of GTPases are associated with specific subcellular compartments, where these proteins are postulated to function in vesicular transport. By screening a human umbilical vein endothelial cell library with degenerate oligonucleotide probes, we have isolated a 1.6-kb cDNA clone encoding a 215-amino-acid protein belonging to the rab family of GTPases. This newly identified rab protein is 81% identical to human rab5, the canine counterpart of which has been localized to the plasma membrane and early endosomes. In light of this homology, we have named this new member of the GTPase superfamily "rab5b." Northern analysis using the rab5b cDNA as a probe revealed a 3.6-kb mRNA in a variety of cell types, including human umbilical vein endothelial cells, K562 erythroleukemia cells, U937 monoblastic cells, and HeLa cells. A fusion protein between glutathione-S-transferase (GST) and rab5b was expressed in bacteria and purified to homogeneity. The recombinant protein was shown to bind GTP and GDP. As is typical of other recombinant rab proteins, the rab5b-GST fusion protein displayed a low intrinsic rate of GTP hydrolysis (0.005/min). An antiserum to rab5b was prepared and used to determine the apparent molecular size and subcellular distribution of the protein. Western blotting with this antibody revealed a 25-kD protein in COS cells transfected with rab5b and in nontransfected HeLa cells.
    [Show full text]
  • Expression Pattern of the PRDX2, RAB1A, RAB1B, RAB5A and RAB25 Genes in Normal and Cancer Cervical Tissues
    INTERNATIONAL JOURNAL OF ONCOLOGY 46: 107-112, 2015 Expression pattern of the PRDX2, RAB1A, RAB1B, RAB5A and RAB25 genes in normal and cancer cervical tissues ANDREJ NIKOSHKOV1, KRISTINA BROLIDEN2, SANAZ ATTARHA1,3, VITALI SVIATOHA3, ANN-CATHRIN HELLSTRÖM4, MIRIAM MINTS1 and SONIA ANDERSSON1 1Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institute, Karolinska University Hospital Solna, 171 76 Stockholm; 2Department of Medicine Solna, Unit of Infectious Diseases, Center for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, 171 76 Stockholm; 3Department of Oncology-Pathology, Karolinska Institute, 171 76 Stockholm; 4Department of Gynecological Oncology, Radiumhemmet, Karolinska University Hospital, 171 76 Stockholm, Sweden Received July 11, 2014; Accepted August 28, 2014 DOI: 10.3892/ijo.2014.2724 Abstract. Cervical cancer is the second most prevalent RAB1B transcript occurs in normal cervical tissue and in malignancy among women worldwide, and additional preinvasive cervical lesions; not in invasive cervical tumors. objective diagnostic markers for this disease are needed. Given the link between cancer development and alternative Introduction splicing, we aimed to analyze the splicing patterns of the PRDX2, RAB1A, RAB1B, RAB5A and RAB25 genes, which Alternative splicing is a process in which either different are associated with different cancers, in normal cervical combinations of exons or parts of exons are employed to tissue, preinvasive cervical lesions and invasive cervical generate new transcripts through the use of alternative-splicing tumors, to identify new objective diagnostic markers. Biopsies sites. More than 90% of human intron-containing genes of normal cervical tissue, preinvasive cervical lesions and undergo alternative splicing, which allows a single transcript invasive cervical tumors, were subjected to rapid amplification to encode a number of RNAs that produce various protein of cDNA 3' ends (3' RACE) RT‑PCR.
    [Show full text]
  • Inhibition of TFG Function Causes Hereditary Axon Degeneration by Impairing Endoplasmic Reticulum Structure
    Inhibition of TFG function causes hereditary axon degeneration by impairing endoplasmic reticulum structure Christian Beetza, Adam Johnsonb, Amber L. Schuhb, Seema Thakurc, Rita-Eva Vargaa, Thomas Fothergilld, Nicole Hertele, Ewa Bomba-Warczakd, Holger Thielef, Gudrun Nürnbergf, Janine Altmüllerf,g, Renu Saxenah, Edwin R. Chapmand, Erik W. Dentd, Peter Nürnbergf,g,i, and Anjon Audhyab,1 aDepartment of Clinical Chemistry and Laboratory Medicine, Jena University Hospital, 07747 Jena, Germany; bDepartment of Biomolecular Chemistry, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706; cDepartment of Genetics and Fetal Medicine, Fortis La Femme, New Delhi 110048, India; dDepartment of Neuroscience, University of Wisconsin Medical School, Madison, WI 53706; eInstitute of Anatomy I, Jena University Hospital, 07740 Jena, Germany; fCologne Centre for Genomics, University of Cologne, 50931 Cologne, Germany; gCologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, 50931 Cologne, Germany; hCentre of Medical Genetics, Sir Ganga Ram Hospital, New Delhi 110048, India; and iCenter for Molecular Medicine Cologne, University of Cologne, 50931 Cologne, Germany Edited by Charles Barlowe, Dartmouth Medical School, and accepted by the Editorial Board February 15, 2013 (received for review October 2, 2012) Hereditary spastic paraplegias are a clinically and genetically hetero- (iii) components of the early secretory pathway that control vesicle geneous group of gait disorders. Their pathological hallmark is a biogenesis and egress (10–16). Among the best-characterized HSP length-dependent distal axonopathy of nerve fibers in the cortico- genes are SPAST, ATL1,andREEP1, all of which encode proteins spinal tract. Involvement of other neurons can cause additional (spastin, atlastin-1, and REEP1, respectively) that potentially neurological symptoms, which define a diverse set of complex regulate ER organization.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0132691 A1 Khvorova Et Al
    US 2008O132691A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0132691 A1 KhVOrOVa et al. (43) Pub. Date: Jun. 5, 2008 (54) SIRNA TARGETING KINASE INSERT Related U.S. Application Data DOMAIN RECEPTOR (KDR) (63) Continuation-in-part of application No. 10/940,892, filed on Sep. 14, 2004, which is a continuation of (75) Inventors: Anastasia Khvorova, Boulder, CO application No. PCT/US04/14885, filed on May 12, (US); Angela Reynolds, Conifer, 2004, Continuation-in-part of application No. 10/714, CO (US); Devin Leake, Denver, 333, filed on Nov. 14, 2003. CO (US); William Marshall, (60) Provisional application No. 60/426,137, filed on Nov. Boulder, CO (US); Steven Read, 14, 2002, provisional application No. 60/502,050, Denver, CO (US); Stephen filed on Sep. 10, 2003. Scaringe, Lafayette, CO (US) Publication Classification Correspondence Address: (51) Int. C. KALOW & SPRINGUT LLP C7H 2L/02 (2006.01) 488 MADISONAVENUE, 19TH FLOOR (52) U.S. Cl. ....................................................... 536/24.5 NEW YORK, NY 10022 (57) ABSTRACT Efficient sequence specific gene silencing is possible through (73) Assignee: DHARMACON, INC., Lafayette, the use of siRNA technology. By selecting particular siRNAs CO (US) by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for (21) Appl. No.: 11/978,107 silencing genes. Methods, compositions, and kits generated through rational design of siRNAS are disclosed including (22) Filed: Oct. 26, 2007 those directed to nucleotide sequences for KDR. s S & 3 & SSSSSSSSSSS k kD CHC & 17O CLCa H EEA 1-> k O-Actinin-> --, -er is a set sat -100 DynII-> ..
    [Show full text]